Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring stage II pancreatic cancer, stage III pancreatic cancer, recurrent pancreatic cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed pancreatic cancer Locally advanced disease Unresectable disease requiring radiotherapy PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST or ALT < grade 2 elevation Bilirubin ≤ 2.0 mg/dL* NOTE: *Prior biliary stent procedure to normalize bilirubin levels allowed Renal Creatinine ≤ 1.5 times normal Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No peripheral neuropathy ≥ grade 2 No known allergy to imidazole drugs, including any of the following: Clotrimazole Ketoconazole Miconazole Econazole Fenticonazole Isoconazole Sulconazole Tioconazole Terconazole PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy At least 4 weeks since prior experimental or standard chemotherapy and recovered No concurrent experimental chemotherapy Endocrine therapy Not specified Radiotherapy No prior upper abdominal radiotherapy Surgery Not specified
Sites / Locations
- Abramson Cancer Center of the University of Pennsylvania